-
Bufalin–CRISPR Nanomedicine in Colorectal Cancer
2026-10-01
A 2025 Materials Today Bio study describes calcium lactate nanoparticles that co-deliver bufalin and a CD47-targeting CRISPR/Cas9 ribonucleoprotein to combine tumor-cell killing with macrophage reprogramming. The reported design links pyroptosis, apoptosis, reduced antiphagocytic signaling, and M1 macrophage activity into a coordinated preclinical immunotherapy strategy.
-
EdU, BaP, and the Translational Cell-Cycle Signal
2026-10-01
BaP-driven prostate cancer progression illustrates why DNA synthesis, immune context, and tumor growth must be measured together. This thought-leadership article explains how EdU-based flow cytometry can strengthen mechanistic studies, pharmacodynamic decisions, and genotoxicity testing while clarifying the limits of proliferation-only readouts.
-
IR-820: New Indocyanine Green Imaging Workflows
2026-09-30
IR-820 (New Indocyanine Green) supports reproducible near-infrared fluorescence imaging across vascular mapping, tumor localization, and diseased tissue quantification. This guide translates the optical properties of the free dye into practical workflows while distinguishing validated imaging use from exploratory nanoparticle and photothermal applications.
-
AngII Drives M1 Polarization via Cx43/NF-κB
2026-09-30
The reference study identifies connexin 43 and NF-κB signaling as a mechanistic link between angiotensin II exposure and pro-inflammatory M1 polarization in RAW264.7 macrophages. Its combined molecular profiling and inhibitor-based design provides a useful framework for studying Cx43-dependent inflammation while also highlighting the need to distinguish macrophage findings from evidence in neuroglial and ischemic models.
-
Viral RIPK3 Degradation and Neddylation Biology
2026-09-29
The reference study identifies a cowpox virus and orthopoxvirus strategy that recruits SCF machinery to target RIPK3 for ubiquitin-proteasome degradation, thereby reshaping necroptosis, inflammation, and viral pathogenesis. Its combination of screening, viral genetics, and mouse infection models provides a framework for studying how host-directed protein degradation influences infection outcomes.
-
AP20187 for Causal Control of Immune Signaling
2026-09-29
AP20187 is a chemical inducer of dimerization that can convert descriptive immune observations into experimentally testable causal models. This article connects conditional protein activation with chronic intermittent hypoxia research while defining assay controls, handling requirements, and translational limits.
-
Losmapimod: Rethinking p38 Inhibition in Translation
2026-09-28
Losmapimod offers translational researchers a well-characterized way to interrogate p38α/β signaling across inflammatory and vascular models. New structural work on p38α dephosphorylation adds an important design question—but does not establish that Losmapimod shares the reported dual-action mechanism.
-
DiscoveryProbe Natural Product Library Plus: Assay Logic
2026-09-27
The DiscoveryProbe Natural Product Library Plus supports diverse, automation-ready screening, but a strong hit is only the start of a mechanistic argument. This article explains how to connect enzyme inhibition to parasite-cell effects while accounting for assay interference, target attribution, and selectivity.
-
LBP Restores Muscle Mitochondrial Quality in Obesity
2026-09-26
Ren et al. report that Lycium barbarum polysaccharide (LBP) improves high-fat-diet-associated skeletal muscle changes alongside AMPK/PINK1/Parkin-mediated mitophagy. Inhibitor and Parkin-knockdown experiments support a role for this pathway, while the findings remain preclinical and do not establish LBP as a treatment for human sarcopenic obesity.
-
Plk1 Control of p31comet in Checkpoint Disassembly
2026-09-26
Kaisari and colleagues show that Polo-like kinase 1 (Plk1) phosphorylates p31comet at S102 and suppresses its cooperation with TRIP13 in disassembling mitotic checkpoint complexes. The work identifies a regulatory brake that may help preserve checkpoint activity while it is needed, while also suggesting specific biochemical readouts for studying checkpoint silencing.
-
Anti-ROR1 Antibody: Applied Research Workflows
2026-09-25
Use Zilovertamab to test ROR1 blockade in target-verified human-cell assays, with practical ELISA, FACS, and functional-assay workflows. A DON liver-injury study offers a useful model-design framework—but the ROR1 connection remains an exploratory hypothesis, not an established mechanism.
-
LBP Protects Muscle Through AMPK-Linked Mitophagy
2026-09-25
A 2025 study reports that Lycium barbarum polysaccharide (LBP) improved metabolic and skeletal-muscle outcomes in high-fat-diet models, with evidence implicating AMPK/PINK1/Parkin-mediated mitophagy. Pharmacological AMPK inhibition and Parkin knockdown weakened the reported benefits, supporting a pathway-dependent effect while leaving questions about dose, mitophagy flux, and relevance to human sarcopenic obesity open.
-
PLGA Microspheres for Cartilage Drug Delivery
2026-09-24
A 2026 study shows that PLGA microsphere size and surface chemistry shape cartilage transport, while particle movement cannot be explained adequately by conventional diffusion models alone. It also finds that PEGylation can preserve hydrocortisone-17-butyrate during release, highlighting the need to evaluate drug stability alongside delivery kinetics.
-
Palonosetron hydrochloride: Bench-to-assay guide
2026-09-24
Use Palonosetron hydrochloride to probe 5-HT3 receptor signaling with subnanomolar potency, then extend the workflow to renal transporter assays as a separate research question. This guide translates receptor-binding evidence into practical assay choices, controls, and troubleshooting steps without treating docking results as proof of biological activity.
-
ATRX Loss and RTK Sensitivity in High-Grade Glioma
2026-09-23
The reference study identifies ATRX deficiency as a cellular context associated with increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma models. Its combination findings with temozolomide support incorporating ATRX status into experimental design and into the interpretation of future targeted-therapy studies, while remaining hypothesis-generating rather than clinically conclusive.